LENZ Therapeutics (NASDAQ:LENZ) Given Outperform Rating at Leerink Partnrs

Leerink Partnrs reiterated their outperform rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note released on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.51) EPS, Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

A number of other research analysts have also recently issued reports on the stock. Piper Sandler initiated coverage on shares of LENZ Therapeutics in a research report on Wednesday, March 27th. They set an overweight rating and a $28.00 price target for the company. William Blair initiated coverage on shares of LENZ Therapeutics in a research report on Monday. They set an outperform rating for the company. Citigroup initiated coverage on shares of LENZ Therapeutics in a research report on Wednesday, April 10th. They set a buy rating and a $34.00 price target for the company. Finally, SVB Leerink started coverage on shares of LENZ Therapeutics in a research report on Monday. They set an outperform rating and a $32.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, LENZ Therapeutics has an average rating of Buy and an average target price of $31.33.

LENZ Therapeutics Price Performance

NASDAQ LENZ traded down $2.22 during trading hours on Monday, reaching $17.70. 84,141 shares of the company’s stock traded hands, compared to its average volume of 58,317. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82. The stock has a market cap of $147.26 million, a P/E ratio of -1.13 and a beta of 0.20.

Insider Buying and Selling

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. acquired 998,009 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The shares were bought at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the acquisition, the director now owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 38.40% of the stock is currently owned by insiders.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.